What the FDA labels say about taking them together
Doxorubicin and valganciclovir
Valganciclovir's FDA label of December 8, 2025 names doxorubicin in its drug interactions section; the doxorubicin labels PlainMeds reads (2) do not name valganciclovir. The valganciclovir label: “Because of potential for higher toxicity, coadministration with VALCYTE should be considered only if the potential benefits are judged to outweigh the risks.”
Check it at the source: the doxorubicin FDA label on DailyMed (effective May 5, 2026, Pfizer Laboratories Div Pfizer Inc); the valganciclovir FDA label on DailyMed (effective December 8, 2025, H2-Pharma, LLC).
What does the doxorubicin label say about valganciclovir?
Doxorubicin's label (effective May 5, 2026) and its 1 other brand-application label do not name valganciclovir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Doxorubicin Hydrochloride), Pfizer Laboratories Div Pfizer Inc, effective May 5, 2026 (SPL set 1fd148fb-0fbc-4b6f-b790-23546fb46a71), via openFDA; the full label on DailyMed
What does the valganciclovir label say about doxorubicin?
Valganciclovir label, drug interactionsName of the Concomitant Drug: Other drugs associated with myelosuppression or nephrotoxicity (e.g., adriamycin, dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine, and zidovudine); Change in the Concentration of Ganciclovir or Concomitant Drug: Unknown; Clinical Comment: Because of potential for higher toxicity, coadministration with VALCYTE should be considered only if the potential benefits are judged to outweigh the risks.
Source: FDA drug label (Valcyte), NDA021304 (Cheplapharm), as published by H2-Pharma, LLC, effective December 8, 2025 (SPL set 4c517a39-2ded-4c5a-8d56-276853414b31), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Doxorubicin | Valganciclovir | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma, Breast cancer | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $1.91 per tablet 450 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once